



EMLc

ATC codes: L04AB04

Indication	Rheumatoid arthritis ICD11 code: FA20
INN	Adalimumab
Medicine type	Biological agent
List type	Complementary (EML) (EMLc)
Additional notes	EML: certolizumab pegol, etanercept, golimumab and infliximab are alternatives, including quality-assured biosimilars. EMLc: etanercept and infliximab are alternatives, including quality-assured biosimilars.
Formulations	Parenteral > General injections > SC: 40 mg per 0.8 mL ; 40 mg per 0.4 mL ; 10 mg per 0.2 mL (EMLc) ; 20 mg per 0.4 mL (EMLc)
EML status history	First added in 2019 (TRS 1021) Changed in 2023 (TRS 1049)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	certolizumab pegol (ATC codes: L04AB05) etanercept (ATC codes: L04AB01) golimumab (ATC codes: L04AB06) infliximab (ATC codes: L04AB02)
Patent information	Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org ↗ Read more about patents. ↗
Tags	Biological
Wikipedia	Adalimumab ↗
DrugBank	Adalimumab ↗

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of new strength formulations of adalimumab (injection 10 mg/0.2 mL and 20 mg/0.4 mL) to the EMLc.

